Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 13, 2026
Rhea-AI Summary
Talphera (Nasdaq: TLPH) will release Q1 2026 financial results after market close on Wednesday, May 13, 2026, followed by a live webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT.
The webcast includes a slide presentation; a replay will be available on the Talphera investor website for 90 days. Dial-in details and conference ID 24180 are provided for live participation.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Ahead of the Q1 2026 call announcement, TLPH was down 3.63% with mixed peer moves: AYTU -0.78%, GELS -20.16%, FLGC +5.29%, TXMD +2.01%, IXHL +4.69%, indicating stock-specific dynamics rather than a unified sector trend.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 23 | Q4 2025 earnings | Positive | -3.8% | Q4 and 2025 results, NEPHRO enrollment at 50%, financing and cash update. |
| Nov 12 | Q3 2025 earnings | Positive | -18.6% | Q3 results, private placement tranche, cash position and expense guidance cut. |
| Aug 14 | Q2 2025 earnings | Positive | -1.0% | Q2 results, reduced operating expenses, trial enrollment update and new financing. |
| May 14 | Q1 2025 earnings | Positive | -3.9% | Q1 results, FDA-approved patient reduction, improved loss and added financing. |
| Mar 31 | FY 2024 earnings | Positive | +7.1% | Q4 and 2024 results, NEPHRO design change, cash and expense improvements. |
Earnings and financial updates have often been followed by negative one-day moves despite operational or financial progress updates.
Over the last five earnings-related events from March 31, 2025 to March 23, 2026, Talphera’s announcements combined financial results, NEPHRO CRRT trial progress, and financing activities. Four of these earnings updates saw negative one-day price reactions, including moves of -18.6% and -3.92%, while only one, on March 31, 2025, produced a positive reaction of 7.07%. The newly scheduled Q1 2026 call fits into this ongoing cadence of earnings plus pipeline updates.
Historical Comparison
Past earnings-related releases averaged a -4.05% one-day move. Today’s Q1 2026 call scheduling continues this earnings-driven news pattern without adding new financial metrics yet.
Earnings updates consistently pair financial results with NEPHRO CRRT trial milestones and staged financing, tracking both cash runway and registrational progress over time.
Regulatory & Risk Context
An effective S-3 shelf dated March 24, 2026 registers up to 639,931 existing shares and 6,399,316 warrant shares for resale by selling stockholders. The filing specifies Talphera will not receive proceeds from these resales, which are secondary offerings by current holders.
Market Pulse Summary
This announcement schedules Talphera’s Q1 2026 results release and webcast for May 13, 2026, continuing a regular cadence of earnings plus corporate updates. Historically, earnings-tagged news has often produced negative one-day moves, with an average change of -4.05%. Investors may focus on upcoming details around cash, NEPHRO CRRT trial progress, and financing, alongside already-registered resale shares for prior private placement investors.
AI-generated analysis. Not financial advice.
Webcast Information
The webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the webcast link posted within Investors/News & Events/Upcoming Events section. The webcast will include a slide presentation and a replay will be available on the Talphera website for 90 days following the event.
Conference Call Information
Investors who wish to participate in the conference call may do so by dialing 1-800-836-8184 for North American callers, or 1-646-357-8785 (toll applies) for international callers outside of
About Talphera, Inc.
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad® is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA).
This release is intended for investors only. For additional information about Talphera, please visit www.talphera.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/talphera-to-host-first-quarter-financial-results-and-corporate-update-call-and-webcast-on-wednesday-may-13-2026-302764770.html
SOURCE Talphera, Inc.